Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Sep 06, 2024

SELL
$114.22 - $140.1 $185,150 - $227,102
-1,621 Reduced 32.04%
3,439 $477 Million
Q4 2023

Sep 06, 2024

BUY
$75.49 - $124.16 $21,665 - $35,633
287 Added 6.01%
5,060 $628 Million
Q3 2023

Sep 06, 2024

BUY
$86.06 - $137.93 $1,032 - $1,655
12 Added 0.25%
4,773 $445 Million
Q2 2023

Sep 06, 2024

SELL
$112.47 - $130.98 $31,941 - $37,198
-284 Reduced 5.63%
4,761 $612 Million
Q1 2023

Sep 06, 2024

SELL
$104.0 - $122.92 $6,760 - $7,989
-65 Reduced 1.27%
5,045 $586 Million
Q4 2022

Sep 06, 2024

BUY
$84.98 - $122.67 $434,247 - $626,843
5,110 New
5,110 $579 Million

Others Institutions Holding DXCM

About DEXCOM INC


  • Ticker DXCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 386,257,984
  • Market Cap $34.3B
  • Description
  • DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...
More about DXCM
Track This Portfolio

Track Ted Buchan & CO Portfolio

Follow Ted Buchan & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ted Buchan & CO, based on Form 13F filings with the SEC.

News

Stay updated on Ted Buchan & CO with notifications on news.